Alan C Moss

List of Publications by Citations

Source: https://exaly.com/author-pdf/7266581/alan-c-moss-publications-by-citations.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

126 papers

4,566 citations

41 h-index

63 g-index

140 ext. papers

5,239 ext. citations

5.1 avg, IF

5.86 L-index

#	Paper	IF	Citations
126	Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. <i>American Journal of Gastroenterology</i> , 2013 , 108, 40-7; quiz 48	0.7	256
125	Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander?. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1620-7	4.5	177
124	Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results. <i>Cancer Treatment Reviews</i> , 2007 , 33, 213-21	14.4	174
123	Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 1996-2003	4.5	157
122	Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction. <i>European Journal of Gastroenterology and Hepatology</i> , 2007 , 19, 1119-24	2.2	146
121	Increased Intestinal Microbial Diversity Following Fecal Microbiota Transplant for Active Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 2182-90	4.5	128
120	Palliative biliary stents for obstructing pancreatic carcinoma. <i>Cochrane Database of Systematic Reviews</i> , 2006 , CD004200		122
119	Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 1-6	4.5	111
118	Histology Grade Is Independently Associated With Relapse Risk in Patients With Ulcerative Colitis in Clinical Remission: A Prospective Study. <i>American Journal of Gastroenterology</i> , 2016 , 111, 685-90	0.7	101
117	Interventions for prevention of post-operative recurrence of Crohn's disease. <i>The Cochrane Library</i> , 2009 , CD006873	5.2	99
116	The utility of capsule endoscopy in patients with suspected Crohn's disease. <i>American Journal of Gastroenterology</i> , 2009 , 104, 2734-9	0.7	89
115	Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 460-6	6.1	88
114	Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 991-6	6.9	87
113	Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. <i>Journal of Immunology</i> , 2006 , 177, 3355-61	5.3	87
112	The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 37, 786-94	6.1	78
111	Mesalamine in the treatment and maintenance of remission of ulcerative colitis. <i>Expert Review of Clinical Pharmacology</i> , 2012 , 5, 113-23	3.8	74
110	The burden of inflammatory bowel disease: a patient-reported qualitative analysis and development of a conceptual model. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 545-52	4.5	73

109	Low Serum Vitamin D During Remission Increases Risk of Clinical Relapse in Patients With Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 240-246.e1	6.9	70	
108	Systematic Review and Meta-Analysis: Serum Infliximab Levels During Maintenance Therapy and Outcomes in Inflammatory Bowel Disease. <i>Journal of Crohn</i> and Colitis, 2016 , 10, 619-25	1.5	66	
107	CD39 and CD161 modulate Th17 responses in Crohn's disease. <i>Journal of Immunology</i> , 2014 , 193, 3366	-7 3 .3	63	
106	Luminal Extracellular Vesicles (EVs) in Inflammatory Bowel Disease (IBD) Exhibit Proinflammatory Effects on Epithelial Cells and Macrophages. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 1587-95	4.5	63	
105	Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010 , 31, 802-9	6.1	62	
104	Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 1188-97	6.1	61	
103	Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 779-84	4.5	61	
102	Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alpha. <i>Gut</i> , 2007 , 56, 1210-7	19.2	57	
101	Efficacy of IV Buscopan as a muscle relaxant in CT colonography. European Radiology, 2003, 13, 2264-70	0 8	57	
100	Vitamin D in inflammatory bowel disease: more than just a supplement. <i>Current Opinion in Gastroenterology</i> , 2018 , 34, 217-225	3	56	
99	Purinergic signaling during intestinal inflammation. <i>Journal of Molecular Medicine</i> , 2017 , 95, 915-925	5.5	55	
98	Melanin-concentrating hormone as a mediator of intestinal inflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 10613-8	11.5	52	
97	Optimizing the use of biological therapy in patients with inflammatory bowel disease. <i>Gastroenterology Report</i> , 2015 , 3, 63-8	3.3	50	
96	Net1 and Myeov: computationally identified mediators of gastric cancer. <i>British Journal of Cancer</i> , 2006 , 94, 1204-12	8.7	50	
95	Vitamin D levels in adults with Crohn's disease are responsive to disease activity and treatment. <i>Inflammatory Bowel Diseases</i> , 2014 , 20, 856-60	4.5	49	
94	Impact of mucosal inflammation on risk of colorectal neoplasia in patients with ulcerative colitis: a systematic review and meta-analysis. <i>Gastrointestinal Endoscopy</i> , 2017 , 86, 1006-1011.e8	5.2	47	
93	Capsule endoscopy for small-bowel evaluation in Crohn's disease. <i>Gastrointestinal Endoscopy</i> , 2011 , 74, 167-75	5.2	47	
92	NADH oxidase-dependent CD39 expression by CD8(+) T cells modulates interferon gamma responses via generation of adenosine. <i>Nature Communications</i> , 2015 , 6, 8819	17.4	46	

91	CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease. <i>European Journal of Immunology</i> , 2012 , 42, 3062-72	6.1	45
90	Cyclosporine is safe and effective in patients with severe ulcerative colitis. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 107-12	3	45
89	Bilirubin suppresses Th17 immunity in colitis by upregulating CD39. JCI Insight, 2017, 2,	9.9	45
88	SCG3 transcript in peripheral blood is a prognostic biomarker for REST-deficient small cell lung cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 274-83	12.9	44
87	Characterization of human CD39+ Th17 cells with suppressor activity and modulation in inflammatory bowel disease. <i>PLoS ONE</i> , 2014 , 9, e87956	3.7	43
86	Role of Vitamin D in the Natural History of Inflammatory Bowel Disease. <i>Journal of Crohn</i> and <i>Colitis</i> , 2018 , 12, 742-752	1.5	41
85	Prevention of post-operative recurrence of Crohn's disease. <i>World Journal of Gastroenterology</i> , 2014 , 20, 1147-54	5.6	40
84	Screening for tuberculosis and hepatitis B prior to the initiation of anti-tumor necrosis therapy. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 1057-63	4.5	38
83	Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1121-6	5.9	38
82	Heightened Expression of CD39 by Regulatory T Lymphocytes Is Associated with Therapeutic Remission in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2806-14	4.5	37
81	Outcomes after escalation of infliximab therapy in ambulatory patients with moderately active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 562-7	6.1	36
80	The risks and the benefits of mesalazine as a treatment for ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2007 , 6, 99-107	4.1	35
79	ETV4 and Myeov knockdown impairs colon cancer cell line proliferation and invasion. <i>Biochemical and Biophysical Research Communications</i> , 2006 , 345, 216-21	3.4	35
78	In silico gene expression analysisan overview. <i>Molecular Cancer</i> , 2007 , 6, 50	42.1	34
77	Abdominal phlegmons in Crohn's disease: outcomes following antitumor necrosis factor therapy. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 691-6	4.5	32
76	Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2012 , 18, 1608-16	4.5	32
75	Ocular manifestations in a community-based cohort of patients with inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 1393-6	4.5	32
74	Substance P-mediated expression of the pro-angiogenic factor CCN1 modulates the course of colitis. <i>American Journal of Pathology</i> , 2008 , 173, 400-10	5.8	32

(2013-2015)

73	The effects of responsible drinking messages on attentional allocation and drinking behaviour. <i>Addictive Behaviors</i> , 2015 , 44, 94-101	4.2	31
7 ²	The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008 , 28, 221-7	6.1	31
71	Palliative biliary stents for obstructing pancreatic carcinoma. <i>The Cochrane Library</i> , 2006 , CD004200	5.2	30
70	Endoscopic pneumatic dilation versus botulinum toxin injection in the management of primary achalasia. <i>The Cochrane Library</i> , 2014 , CD005046	5.2	28
69	Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis. <i>Cellular Immunology</i> , 2013 , 282, 66-70	4.4	26
68	Clinical results of CT colonoscopy. <i>European Radiology</i> , 2001 , 11, 2188-94	8	26
67	Sexual Dysfunction in Men With Inflammatory Bowel Disease: A New IBD-Specific Scale. <i>Inflammatory Bowel Diseases</i> , 2018 , 24, 310-316	4.5	25
66	A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and semen quality in men with inflammatory bowel disease. <i>Environment International</i> , 2016 , 95, 120-30	12.9	25
65	Mesalamine, but Not Sulfasalazine, Reduces the Risk of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: An Agent-specific Systematic Review and Meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2562-9	4.5	24
64	Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes. <i>Drugs</i> , 2008 , 68, 1089-103	12.1	24
63	Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitisa prospective study. <i>Journal of Crohn and Colitis</i> , 2010 , 4, 171-5	1.5	23
62	Emergency department utilisation for inflammatory bowel disease in the United States from 2006 to 2014. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 913-921	6.1	22
61	Higher serum vitamin D levels are associated with protective serum cytokine profiles in patients with ulcerative colitis. <i>Cytokine</i> , 2018 , 103, 38-45	4	22
60	Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with solid organ transplants: an institutional experience and review of the literature. <i>Transplant Infectious Disease</i> , 2018 , 20, e12967	2.7	21
59	HIF-1⊞nduced xenobiotic transporters promote Th17 responses in Crohn's disease. <i>Journal of Autoimmunity</i> , 2018 , 94, 122-133	15.5	21
58	Curcumin for maintenance of remission in ulcerative colitis. <i>The Cochrane Library</i> , 2012 , 10, CD008424	5.2	21
57	Characterization of circulating microparticle-associated CD39 family ecto-nucleotidases in human plasma. <i>Purinergic Signalling</i> , 2014 , 10, 611-8	3.8	20
56	Prevention of postoperative recurrence of Crohn's disease: what does the evidence support?. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 856-9	4.5	19

55	Steroid-refractory severe ulcerative colitis: what are the available treatment options?. <i>Drugs</i> , 2008 , 68, 1157-67	12.1	18
54	Modulation of lymphocyte-mediated tissue repair by rational design of heterocyclic aryl hydrocarbon receptor agonists. <i>Science Advances</i> , 2020 , 6, eaay8230	14.3	17
53	Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1850-5	0.7	17
52	Impact of concomitant immunomodulator use on long-term outcomes in patients receiving scheduled maintenance infliximab. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 1413-20	4	17
51	A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study. <i>American Journal of Gastroenterology</i> , 2013 , 108, 249-55	0.7	16
50	Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 2873-8	4.5	15
49	Colonic surveillance by CT colonography using axial images only. European Radiology, 2004, 14, 763-7	8	15
48	Prevalence and lifetime risk of endoscopy-related complications among patients with inflammatory bowel disease. <i>Clinical Gastroenterology and Hepatology</i> , 2013 , 11, 1288-93	6.9	14
47	Dibutyl-phthalate exposure from mesalamine medications and serum thyroid hormones in men. <i>International Journal of Hygiene and Environmental Health</i> , 2019 , 222, 101-110	6.9	14
46	The meaning of low-grade inflammation in clinically quiescent inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2014 , 30, 365-9	3	13
45	Expression of Ecto-nucleoside Triphosphate Diphosphohydrolases-2 and -3 in the Enteric Nervous System Affects Inflammation in Experimental Colitis and Crohn's Disease. <i>Journal of Crohn</i> and <i>Colitis</i> , 2017 , 11, 1113-1123	1.5	11
44	MR Enterography of the Ileoanal Pouch: Descriptive Radiologic Analysis With Endoscopic and Pathologic Correlation. <i>American Journal of Roentgenology</i> , 2015 , 205, W478-84	5.4	11
43	Capsule endoscopy in suspected Crohn's disease: "yield" does not equal "diagnosis". <i>American Journal of Gastroenterology</i> , 2010 , 105, 2111; author reply 2111-2	0.7	11
42	Iron Replacement in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2015 , 21, 1976-81	4.5	10
41	Barriers to mesalamine adherence in patients with inflammatory bowel disease: a qualitative analysis. <i>Journal of Managed Care Pharmacy</i> , 2014 , 20, 309-14		10
40	Drug development in inflammatory bowel disease: the role of the FDA. <i>Inflammatory Bowel Diseases</i> , 2011 , 17, 2585-93	4.5	10
39	Adalimumab for cutaneous metastatic Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010 , 16, 723-4	4.5	10
38	A crossover-crossback prospective study of dibutyl-phthalate exposure from mesalamine medications and serum reproductive hormones in men. <i>Environmental Research</i> , 2018 , 160, 121-131	7.9	9

(2009-2014)

37	The use of pharmacological prophylaxis against venous thromboembolism in hospitalised patients with severe active ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014 , 39, 940-8	6.1	9
36	Rifaximin suppresses background intestinal 18F-FDG uptake on PET/CT scans. <i>Nuclear Medicine Communications</i> , 2014 , 35, 1026-31	1.6	9
35	Open conformation tissue transglutaminase testing for celiac dietary assessment. <i>Digestive and Liver Disease</i> , 2012 , 44, 375-8	3.3	9
34	A fatal case of diffuse enteritis after colectomy for ulcerative colitis: a case report and review of the literature. <i>American Journal of Gastroenterology</i> , 2014 , 109, 1086-9	0.7	8
33	Cutaneous Vasculitis in a Patient with Crohn's Disease Treated with Adalimumab. <i>Inflammatory Bowel Diseases</i> , 2017 , 23, E1-E2	4.5	8
32	Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis. Journal of Clinical Gastroenterology, 2014 , 48, 351-5	3	8
31	Inflammatory Bowel Disease Environmental Risk Factors: Diet and Gut Microbiota. <i>Current Gastroenterology Reports</i> , 2020 , 22, 57	5	8
30	Once-daily mesalamine granules for ulcerative colitis. Expert Review of Clinical Immunology, 2010 , 6, 521	l- § 1	7
29	Focal physiologic fluorodeoxyglucose activity in the gastrointestinal tract is located within the colonic lumen. <i>Nuclear Medicine Communications</i> , 2012 , 33, 641-7	1.6	7
28	Reducing the torment of diarrhea: tormentil for active ulcerative colitis. <i>Journal of Clinical Gastroenterology</i> , 2007 , 41, 797-8	3	7
27	Impact of inflammatory bowel disease activity and thiopurine therapy on birth weight: A meta-analysis. <i>World Journal of Gastroenterology</i> , 2017 , 23, 8082-8089	5.6	7
26	The Use and Efficacy of Fecal Microbiota Transplantation for Refractory Clostridium difficile in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, 2704-2710	4.5	6
25	Current and emerging maintenance therapies for ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014 , 8, 359-68	4.2	5
24	Curcumin for maintenance therapy in ulcerative colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2007 , 5, 642; author reply 642	6.9	5
23	Thyroid cancer and Crohn's disease: association or coincidence?. <i>Inflammatory Bowel Diseases</i> , 2006 , 12, 79-80	4.5	5
22	Commentary: impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel diseaseauthors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2013 , 38, 843	6.1	4
21	Combined oral and topical mesalazine treatment for extensive ulcerative colitis. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2006 , 3, 290-3		4
20	Pseudogout after polyethylene glycol bowel cleansing. <i>Journal of Clinical Gastroenterology</i> , 2009 , 43, 95-6	3	3

19	Knowledge Gaps in the Management of Postoperative Crohn's Disease: A US National Survey. <i>Digestive Diseases and Sciences</i> , 2018 , 63, 53-60	4	3
18	C-reactive protein as a predictor of low trough infliximab concentrations in patients who lose response to infliximab. <i>Journal of Digestive Diseases</i> , 2017 , 18, 678-683	3.3	2
17	Development of a repeated measures affective change blindness task. <i>Behavior Research Methods</i> , 2011 , 43, 826-33	6.1	2
16	Gastrointestinal [corrected] stromal tumor of the ampulla of vater mimicking a duodenal ulcer. <i>Clinical Gastroenterology and Hepatology</i> , 2007 , 5, A26	6.9	2
15	Mesalamine in the Initial Therapy of Ulcerative Colitis. <i>Gastroenterology Clinics of North America</i> , 2020 , 49, 689-704	4.4	2
14	Comment on Moshkovska et al. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, E19	4.5	1
13	Lectin-reactive anti-Egal in patients with Crohn's disease: correlation with clinical phenotypes. <i>Inflammatory Bowel Diseases</i> , 2013 , 19, 2796-800	4.5	1
12	Reflux, dyspepsia, and disorders of the foregut. <i>Southern Medical Journal</i> , 2007 , 100, 266-72; quiz 273, 294	0.6	1
11	Health Maintenance Consensus for Adults With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1552-1563	4.5	1
10	Implications of recurrent SARS-CoV-2 outbreaks for IBD management. <i>Frontline Gastroenterology</i> , 2021 , 12, 316-321	2.6	О
9	Reply. Clinical Gastroenterology and Hepatology, 2017, 15, 1136-1137	6.9	
8	P-108 Infliximab-Associated Suppression of Cytokine Release by Mucosal Explants Predicts Success of Anti-TNF Therapy in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016 , 22, S43-S44	4.5	
7	True costs of infliximab testing and administration. <i>Clinical Gastroenterology and Hepatology</i> , 2014 , 12, 346	6.9	
6	Commentary: outcomes after escalation of infliximab in moderately active ulcerative colitis author's reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2012 , 35, 958-959	6.1	
5	Treg CD39 expression as a modulator of intestinal inflammation in Crohn's DiseaseP-240 <i>Inflammatory Bowel Diseases</i> , 2011 , 17, S83	4.5	
4	Efficacy of Curcumin (turmeric) in the treatment of Inflammatory Bowel Disease: A systematic reviewP-15 <i>Inflammatory Bowel Diseases</i> , 2011 , 17, S16	4.5	
3	5-aminosalicylates to prevent relapse of Crohn's disease after surgery. <i>American Journal of Gastroenterology</i> , 2012 , 107, 487; author reply 487-8	0.7	
2	Attitudes to peer review as a competence assurance structureresults of a survey of Irish physicians. <i>Irish Journal of Medical Science</i> , 2005 , 174, 43-6	1.9	

Crohn® disease stricture evaluation and management. *Techniques in Gastrointestinal Endoscopy*, **2016**, 18, 136-144

0.8